deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT05155293

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (ALVOEYE)

A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared With EU-Eylea® in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALVOEYE)

Sponsor: Alvotech Swiss AG

Conditions Neovascular (Wet) AMD
Interventions AVT06 (proposed aflibercept biosimilar) Eylea® (Aflibercept)
Updated 11 times since 2022 Last updated: Sep 26, 2024 Started: Jun 28, 2022 Primary completion: Nov 17, 2023 Completion: Sep 23, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Neovascular (Wet) AMD and is currently completed. Alvotech Swiss AG leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshotRecruiting~Feb 2023 – ~May 2023 · 3 months · monthly snapshotRecruiting~May 2023 – ~Jul 2023 · 2 months · monthly snapshotRecruiting~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshotRecruiting~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshotActive Not Recruiting~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshotActive Not Recruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotActive Not Recruiting~Oct 2024 – present · 23 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Oct 2024 — Present [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 6 earlier versions

  1. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  3. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  4. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE3

  5. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  6. Jan 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alvotech Swiss AG
Data source: Alvotech Swiss AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations